DRTS · NASDAQ

Alpha Tau Medical Ltd

Q: How do I get DRTS news from the API?

Call GET /v1/news?tickers=DRTS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.

$13.15 -0.23 (-1.72%)

Company overview

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company that engages in the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer in Israel and the United States. Its Alpha-DaRT technology is used in clinical trials for skin, oral, pancreatic, and breast cancers, as well as preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and other cancers. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Sector: Healthcare
Industry: Medical - Equipment & Services
Exchange: NASDAQ
Market cap: $1.2B
Employees: 118
Headquarters: Jerusalem
Website: alphatau.com
CEO: Uzi Sofer
Listed: March 8, 2021
P/E: -19.63
Dividend yield: 0.00%

Company financials

Revenue: $0.00
Gross profit: $0.00
Operating income: -$46.3M
EBITDA: -$46.2M
Net income: -$56.9M
EPS: -$0.67
Total assets: $109M
Total debt: $14.3M
Earnings yield: -5.10%

Price chart

DRTS 1D NASDAQ O13.51H13.62L13.25C13.35-0.16 (-1.18%)Vol401.57K

News

Ticker	Type	Headline	Source	Published
DRTSAlpha Tau Medical Ltd	Press release	Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange	GlobeNewswire	Oct 29, 12:14:57 PM ET
DRTSAlpha Tau Medical Ltd	Press release	Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea	GlobeNewswire	Oct 22, 8:30:00 AM ET
DRTSAlpha Tau Medical Ltd	Press release	Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting	GlobeNewswire	Oct 19, 8:30:00 AM ET
DRTSAlpha Tau Medical Ltd	Press release	Alpha Tau to Participate in October Investor Conferences	GlobeNewsWire	Oct 5, 9:45:00 AM ET
DRTSAlpha Tau Medical Ltd	Stock news	Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More	Seeking Alpha	Sep 11, 3:53:39 PM ET
DRTSAlpha Tau Medical Ltd	Stock news	Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough	Seeking Alpha	Sep 4, 11:56:47 AM ET
DRTSAlpha Tau Medical Ltd	Press release	Alpha Tau to Participate in September Investor Conferences	GlobeNewswire	Sep 2, 8:00:00 AM ET
DRTSAlpha Tau Medical Ltd	Press release	Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions	GlobeNewsWire	Aug 31, 8:00:00 AM ET
DRTSAlpha Tau Medical Ltd	Stock news	PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS) Critical Contrast	Defense World	Aug 13, 3:33:52 AM ET
DRTSAlpha Tau Medical Ltd	Press release	Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Stud.	GlobeNewsWire	Jul 21, 8:30:00 AM ET
DRTSAlpha Tau Medical Ltd	Stock news	Alpha Tau Medical (NASDAQ:DRTS) Trading 7.1% Higher – Here’s Why	Defense World	Jul 19, 4:01:47 AM ET
DRTSAlpha Tau Medical Ltd	Press release	Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center	GlobeNewsWire	Jul 15, 8:30:00 AM ET
DRTSAlpha Tau Medical Ltd	Stock news	New Strong Sell Stocks for July 7th	Zacks Investment Research	Jul 7, 9:36:09 AM ET
DRTSAlpha Tau Medical Ltd	Press release	Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients	GlobeNewsWire	Jun 3, 8:30:00 AM ET
DRTSAlpha Tau Medical Ltd	Press release	Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting	GlobeNewsWire	Jun 1, 9:00:00 AM ET
DRTSAlpha Tau Medical Ltd	Stock news	Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears	MarketBeat	May 29, 9:04:16 AM ET
DRTSAlpha Tau Medical Ltd	Press release	Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update	GlobeNewsWire	May 18, 4:01:00 PM ET
DRTSAlpha Tau Medical Ltd	Press release	Alpha Tau to Participate in May Investor Conferences	GlobeNewsWire	May 18, 8:30:00 AM ET
DRTSAlpha Tau Medical Ltd	Stock news	Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally	Benzinga	May 11, 12:06:07 PM ET
DRTSAlpha Tau Medical Ltd	Stock news	Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study	MarketBeat	May 11, 10:09:01 AM ET

FAQ

Questions about Alpha Tau Medical Ltd

What does Alpha Tau Medical Ltd do?

What is DRTS's market cap?

Alpha Tau Medical Ltd (DRTS) is a listed stock with a live quote. The latest market cap on this page is $1.2B.

Where is Alpha Tau Medical Ltd headquartered?

Alpha Tau Medical Ltd is headquartered in Jerusalem.

How do I get DRTS news from the API?

Call GET /v1/news?tickers=DRTS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.

How far back does DRTS news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for DRTS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.

Is the DRTS price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs